Relationship between physician-adjudicated adverse events and patient-reported health-related quality of life in a phase II clinical trial (NCT01143402) of patients with metastatic uveal melanoma.
Journal of Cancer Research and Clinical Oncology.
Times cited: 1
A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an oral MEK1/2 inhibitor, in relapsed/refractory multiple myeloma.
Clinical Cancer Research.
Times cited: 9
Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: A randomized clinical trial.
JAMA - Journal of the American Medical Association.
Times cited: 149